ライフサイエンスコーパス: carnitine palmitoyltransferase 1

1 human mitochondria-specific protein and the carnitine palmitoyltransferase 1.

2 Activity of carnitine palmitoyltransferase-1, a key enzyme controlli

3 l-CoA is a potent inhibitor of mitochondrial carnitine palmitoyltransferase-1, a key enzyme involved

4 reflect a metabolic bottleneck downstream of carnitine palmitoyltransferase-1, a mitochondrial enzyme

5 acids (LCFAs) at the level of reduced CPT1 (carnitine palmitoyltransferase 1) activity at the outer

6 nthase, acetyl coenzyme A carboxylase 2, and carnitine palmitoyltransferase 1 alpha) in both WT and A

7 lipogenesis and decrease in the activity of carnitine palmitoyltransferase-1 and total energy expend

8 pyruvate carboxykinase, fatty acid synthase, carnitine palmitoyltransferase 1, and glucokinase among

9 genes of fatty acid oxidation such as Cpt-1 (carnitine palmitoyltransferase-1) as well as Pgc-1alpha

10 tty acid oxidation through the inhibition of carnitine palmitoyltransferase 1 by its product malonyl-

11 short-chain fatty acids (SCFAs) that bypass carnitine palmitoyltransferase 1, could similarly suppor

12 cid oxidation by stimulating the activity of carnitine palmitoyltransferase-1 (CPT-1) and inhibiting

13 In addition, carnitine palmitoyltransferase-1 (CPT-1) inhibitor up-re

14 atty acids (LCFAs) into the mitochondria via carnitine palmitoyltransferase-1 (CPT-1) is inhibited by

15 Remarkably, 30 does not activate carnitine palmitoyltransferase-1 (CPT-1) nor induces in

16 l downstream effects including inhibition of carnitine palmitoyltransferase-1 (CPT-1) with resultant

17 ns, C75 inhibits FAS activity and stimulates carnitine palmitoyltransferase-1 (CPT-1), consistent wit

18 complex I was associated with a decrease in carnitine palmitoyltransferase 1 (cPT1) and cPT2 levels.

19 c remodeling, with an early isoform shift of carnitine palmitoyltransferase 1 (CPT1) toward increased

20 the content of malonyl-CoA, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), and, thus, mito

21 The enzyme carnitine palmitoyltransferase 1 (CPT1), which is anchor

22 yl-CoA concentrations are known to derepress carnitine palmitoyltransferase 1 (CPT1).

23 Carnitine palmitoyltransferase-1 (CPT1) is a rate-limiti

24 The enzyme carnitine palmitoyltransferase-1 (CPT1) regulates long-c

25 Malonyl-CoA is an established inhibitor of carnitine palmitoyltransferase-1 (CPT1), an outer mitoch

26 o this end, we targeted the liver isoform of carnitine palmitoyltransferase-1 (encoded by the CPT1A g

27 phorylated acetyl-coenzyme A carboxylase and carnitine palmitoyltransferase 1 in the liver.

28 quent treatment of mice for 4 weeks with the carnitine palmitoyltransferase-1 inhibitor, oxfenicine (

29 omir) consumed diets containing 0.01% of the carnitine palmitoyltransferase-1 inhibitor, R-etomoxir,

30 of the lipogenic pool but diminution of the carnitine palmitoyltransferase 1 inhibitory pool under c

31 CPT1 (carnitine palmitoyltransferase 1) is a rate-limiting enz

32 Using a skeletal muscle-specific carnitine palmitoyltransferase-1 KO model, we show that

33 r-activated receptor alpha protein and liver-carnitine palmitoyltransferase-1 (l-CPT-1) mRNA increase

34 lcohol-induced liver injury due to increased carnitine palmitoyltransferase-1, phosphorylated 5'AMP-a

35 R) delta to the PPAR response element on the carnitine palmitoyltransferase 1 promoter.

36 ated with changes in ACSL1 (R(2) = 0.39) and carnitine palmitoyltransferase 1 (R(2) = 0.30) expressio

37 ated receptor alpha and induction of hepatic carnitine palmitoyltransferase 1, suggesting increased e

38 unction through its allosteric inhibition of carnitine palmitoyltransferase 1, the enzyme that normal

39 Similarly, carnitine palmitoyltransferase-1 was inhibited after rep